Deep Genomics raises $180m funding to expand AI platform for RNA therapies

Deep Genomics筹集1.8亿美元资金扩大RNA治疗AI平台

2021-07-30 02:00:32 PHARMACEUTICAL

本文共596个字,阅读需2分钟

Deep Genomics has raised $180m funding in Series C financing round to expand its artificial intelligence (AI) discovery platform for ‘Programmable’ RNA therapeutics and scale its portfolio into the clinic. The financing round is led by SoftBank Vision Fund 2, with other new investors including Canadian Pension Plan Investment Board (CPP Investments), Alexandria Venture Investments, Khosla Ventures, Fidelity Management & Research Company, Amplitude Ventures, Magnetic Ventures, and True Ventures. Founded in 2015, Deep Genomics uses AI and machine learning to programme and prioritise RNA therapies for almost all genetic diseases. The funding will also be used to expand the company’s AI Workbench platform, a suite of predictive systems that has made billions of predictions across the entire human genome, for many genetic variants, and novel compounds. The proceeds will also support Deep Genomics’ plans to advance four programmes into the clinic by 2023 and start a large-scale effort to generate biological data across 100 genes to identify novel targets, mechanisms, and preclinical programmes. Deep Genomics founder and CEO Brendan Frey said: “This financing further validates the significant advances in our AI discovery platform and growth of our proprietary preclinical pipeline. “Our AI Workbench enables us to precisely program RNA therapeutics, much like computer code, to perform a wide range of functions. “This AI Workbench, paired with terabytes of proprietary data, enables us to tackle the enormous complexity of RNA biology and identify novel targets, mechanisms, and RNA therapeutics, which cannot be found without AI.”
Deep Genomics在C轮融资中筹集了1.8亿美元资金,以扩大其“可编程”RNA治疗的人工智能(AI)发现平台,并将其投资组合扩大到临床。 融资轮由软银愿景基金2牵头,其他新投资者包括加拿大养老金计划投资委员会(CPP Investments)、亚历山大风险投资公司、科斯拉风险投资公司、富达管理研究公司、振幅风险投资公司、磁性风险投资公司和True Ventures。 Deep Genomics成立于2015年,使用人工智能和机器学习来编程和优先考虑几乎所有遗传病的RNA治疗。 这笔资金还将用于扩展该公司的AI工作台平台,这是一套预测系统,已经对整个人类基因组、许多基因变体和新化合物做出了数十亿次预测。 收益还将支持深度基因组公司的计划,即到2023年将四个项目推进到临床,并开始大规模努力生成100个基因的生物数据,以识别新的目标、机制和临床前项目。 Deep Genomics创始人兼首席执行官布兰登·弗雷(Brendan Frey)表示:“这笔融资进一步验证了我们人工智能发现平台的重大进展和我们专有临床前管道的增长。 “我们的人工智能工作台使我们能够精确地对RNA治疗进行编程,就像计算机代码一样,以执行广泛的功能。 “这个人工智能工作台与太字节的专有数据配对,使我们能够解决RNA生物学的巨大复杂性,并识别没有人工智能就无法找到的新靶点、机制和RNA治疗方法。”

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文